Pain-related Fear as a Facilitator of Nocebo Hyperalgesia

Not Applicable

Completed

• Conditions: Chronic Pain Syndrome; Fear of Pain; Hyperalgesia; Chronic Pain, Psychogenic
• Interventions: Behavioral: Threat manipulation (control, no threat); Behavioral: Threat manipulation; Behavioral: Conditioning of high pain; Behavioral: Conditioning of moderate pain; Behavioral: Extinction

• Registration Number: NCT04197154
• Lead Sponsor: Leiden University Medical Center

Brief Summary

Nocebo hyperalgesia is characterized by adverse pain outcomes, induced by patients' expectations. In the lab, nocebo effects are commonly studied via classical conditioning, a method that employs pairings of neutral cues/treatments with different pain intensities to install differential pain-related expectations. In such conditioning experiments, participants are typically taught that a (sham) treatment exaggerates their pain, by surreptitiously administering high intensity (e.g. pain) stimuli in combination with this treatment. Verbal suggestions are also often used to inform participants of the supposed adverse effects of such treatments. In nocebo studies, higher pain levels and suggestions that are of more threatening nature may induce fear, thereby adding a crucial element to the experimental manipulation. Since nocebo effects are hypothesized to arise in clinical settings due to a combination of several psychological and cognitive mechanisms, it is important to study the role that factors such as higher pain levels, conditioned pain-related fear, or more threatening verbal suggestions may play in the formation of nocebo hyperalgesia. To date, no studies have focused on the fear-inducing effect that different pain intensities or verbal threat suggestions may have and how this fear, in turn, may strengthen the acquisition of nocebo effects. This study aims to investigate whether higher pain intensity or higher pain-related fear induced via threatening suggestions facilitate the acquisition and hinder subsequent extinction of nocebo hyperalgesia. This study will be conducted at Leiden University.

Detailed Description

The investigators expect that higher pain intensity and/or higher pain-related fear induced via threatening suggestions will lead to stronger acquisition of nocebo hyperalgesia and/or more durable nocebo hyperalgesia after extinction.

Main outcome variables:

* The magnitude of induced nocebo hyperalgesia is defined as the difference in pain ratings for the first nocebo trial compared to the first control trial of the extinction phase.

* The reduction of nocebo hyperalgesia is defined as the change in reported pain between the first and last nocebo trial of the extinction phase.

* Fear levels (for mediation analyses) are measured via eye-blink startle modulation and self-reported fear during nocebo trials (relative to control trials).

For EMG analyses this study follows typical pre-processing of EMG recordings, similar to previous studies. The EMG signal will be digitized at 1,000 Hz from 200 ms before the startle probe until 1,500 ms after probe onset. The startle probe is a 100 dBA burst of white noise with instantaneous rise time presented binaurally for 100 ms through earphones. Each 2-4 consecutive startle probe responses of the same cue (nocebo vs control) will be averaged for further analyses. Participants who exhibited a startle response in less than 20% of trials in the first half of induction will be labeled as non-responders. Trials during which, for example, baseline is higher than startle response peak due to an occasional blink before the probe presentation, will be labelled as non-response or reject trials.

1. Main planned analyses:

To examine whether higher pain stimulation (high-pain nocebo group) leads to stronger nocebo hyperalgesia, as compared to lower pain stimulation (control nocebo group), a 2x2 mixed model analysis of variance (ANOVA) will be performed with group (high-pain nocebo group, control nocebo group) as the between-subjects factor and trial type as within-subjects factor with two levels (first nocebo extinction trial, first control extinction trial).

2. Secondary analyses:

2a. To examine whether an impact of higher pain stimulation on the magnitude of nocebo hyperalgesia was mediated by pain-related fear levels, a mediation analysis will be conducted for the high pain nocebo and control nocebo groups, to assess if fear mediates the relationship between pain levels and the magnitude of nocebo hyperalgesia (calculated difference scores between the first nocebo extinction trial and the first control extinction trial).

2b. To examine whether higher pain-related fear induced via a threat suggestion (high-threat nocebo) led to stronger nocebo hyperalgesia, as compared to no threat suggestion (control nocebo group), a 2x2 mixed model ANOVA will be performed with group (high-threat nocebo, control nocebo group) as the between-subjects factor and trial type as within-subjects factor with two levels (first nocebo extinction trial, first control extinction trial).

2c. To examine whether higher pain stimulation (high-pain nocebo group) led to more durable nocebo effect, as compared to lower pain stimulation (control nocebo group), a 2x2 mixed model ANOVA will be performed with group (high-pain nocebo group, control nocebo group) as the between-subjects factor and trial as within-subjects factor with two levels (first nocebo extinction trial, last nocebo extinction trial).

2d. To examine whether an impact of higher pain stimulation on the durability of nocebo hyperalgesia was mediated by pain-related fear levels, a mediation analysis will be conducted to assess if fear mediates the relationship between pain levels and the magnitude of nocebo hyperalgesia after extinction (calculated difference scores between the first nocebo extinction trial and the last nocebo extinction trial).

2e. To examine whether higher pain-related fear induced via a threat suggestion led to more durable nocebo hyperalgesia, as compared to no threat suggestion, a 2x2 mixed model ANOVA will be performed with group (high-threat nocebo, control nocebo group) as the between-subjects factor and trial as within-subjects factor with two levels (first nocebo extinction trial, last nocebo extinction trial).

Study Timeline

• Study Start: 2019-10-14
• Study First Submitted: 2019-12-09
• Study First Submitted QC: 2019-12-11
• Study First Posted: 2019-12-12
• Status Verified: 2020-02
• Primary Completion: 2020-02-14
• Study Completion: 2020-02-14
• Last Update Submitted: 2020-02-18
• Last Update Posted: 2020-02-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

• Aged 17 - 35 years
• Good understanding of the English language
• Normal or corrected to normal vision

Exclusion Criteria

• Ever having experienced serious medical or psychiatric conditions (e.g., heart or lung disease, panic attacks, drug addiction, clinical depression),
• Ever having experienced chronic pain complaints (pain for more than 6 months),
• Experiencing acute physical pain (e.g., headache; above 3 on a 10-point NRS scale), or having used pain medication on the day of testing,
• Pregnancy or breastfeeding,
• Having recent injuries to the wrists or arms on the day of testing,
• Previous participation in this or similar studies (e.g., using conditioning or thermal pain).
• Having consumed psychotropic medication, recreational drugs, analgesic medication, or more than 3 units of alcohol, in the 24 hours prior to the study appointment.
• After inclusion, participants who do not reach a sensation of high pain (at least 6 on the NRS) with the highest administered temperature or participants who appear unable to distinguish between moderate and high pain stimuli (reporting at least a mean difference of 1.5 NRS points between nocebo and control trials during induction) will also be excluded.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1. Control nocebo group	Threat manipulation (control, no threat)	Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and no threat suggestions.
2. High-pain nocebo group	Threat manipulation (control, no threat)	Conditioning and extinction of a nocebo response using higher pain stimuli, nocebo negative suggestions, and no threat suggestions.
2. High-pain nocebo group	Conditioning of high pain	Conditioning and extinction of a nocebo response using higher pain stimuli, nocebo negative suggestions, and no threat suggestions.
1. Control nocebo group	Conditioning of moderate pain	Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and no threat suggestions.
1. Control nocebo group	Extinction	Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and no threat suggestions.
3. High-threat nocebo	Conditioning of moderate pain	Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and threat suggestions (i.e., fear-inducing suggestions).
3. High-threat nocebo	Extinction	Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and threat suggestions (i.e., fear-inducing suggestions).
2. High-pain nocebo group	Extinction	Conditioning and extinction of a nocebo response using higher pain stimuli, nocebo negative suggestions, and no threat suggestions.
3. High-threat nocebo	Threat manipulation	Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and threat suggestions (i.e., fear-inducing suggestions).

Primary Outcome Measures

Name	Time	Method
Magnitude of nocebo hyperalgesia	On the testing day, in the first trials of the extinction phase	The magnitude of induced nocebo hyperalgesia is defined as the difference in pain ratings for the first nocebo trial compared to the first control trial of the extinction phase.

Secondary Outcome Measures

Name	Time	Method
Reduction of nocebo hyperalgesia	On the testing day, in the extinction phase	The reduction of nocebo hyperalgesia is defined as the change in reported pain between the first and last nocebo trial of the extinction phase.

Trial Locations

Locations (1)

Leiden University; 🇳🇱 Leiden, South Holland, Netherlands